NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,443 | +2068.2% | 77,978 | +1993.9% | 0.00% | – |
| Q2 2023 | $2,142 | -96.5% | 3,724 | -95.7% | 0.00% | – |
| Q1 2023 | $61,164 | -79.1% | 87,017 | -32.9% | 0.00% | – |
| Q4 2022 | $292,889 | -31.6% | 129,597 | -3.1% | 0.00% | – |
| Q3 2022 | $428,000 | -36.5% | 133,678 | -24.6% | 0.00% | -100.0% |
| Q2 2022 | $674,000 | -42.4% | 177,386 | -18.4% | 0.00% | 0.0% |
| Q1 2022 | $1,171,000 | -27.6% | 217,374 | +81.6% | 0.00% | 0.0% |
| Q4 2021 | $1,617,000 | +47.3% | 119,690 | +95.6% | 0.00% | 0.0% |
| Q3 2021 | $1,098,000 | -30.1% | 61,186 | -33.1% | 0.00% | 0.0% |
| Q2 2021 | $1,570,000 | +19.6% | 91,485 | +39.4% | 0.00% | 0.0% |
| Q1 2021 | $1,313,000 | -67.1% | 65,618 | -72.0% | 0.00% | -50.0% |
| Q4 2020 | $3,988,000 | +9.2% | 234,604 | +6.6% | 0.00% | 0.0% |
| Q3 2020 | $3,652,000 | -58.9% | 220,120 | -42.6% | 0.00% | -71.4% |
| Q2 2020 | $8,886,000 | +18.9% | 383,629 | -8.4% | 0.01% | 0.0% |
| Q1 2020 | $7,475,000 | +3.3% | 418,741 | +24.8% | 0.01% | +16.7% |
| Q4 2019 | $7,239,000 | +18.8% | 335,413 | +0.3% | 0.01% | +20.0% |
| Q3 2019 | $6,092,000 | -24.7% | 334,432 | +47.0% | 0.01% | -16.7% |
| Q2 2019 | $8,094,000 | +15.6% | 227,503 | +9.2% | 0.01% | -25.0% |
| Q1 2019 | $6,999,000 | -12.2% | 208,309 | -14.2% | 0.01% | 0.0% |
| Q4 2018 | $7,976,000 | -7.3% | 242,658 | +72.0% | 0.01% | 0.0% |
| Q3 2018 | $8,602,000 | +17.6% | 141,114 | -5.8% | 0.01% | +14.3% |
| Q2 2018 | $7,312,000 | +46.1% | 149,751 | +218.0% | 0.01% | +75.0% |
| Q1 2018 | $5,005,000 | +285.3% | 47,094 | +116.4% | 0.00% | +300.0% |
| Q4 2017 | $1,299,000 | -58.6% | 21,759 | -83.4% | 0.00% | -50.0% |
| Q3 2017 | $3,138,000 | -27.4% | 130,736 | -40.8% | 0.00% | -50.0% |
| Q2 2017 | $4,321,000 | -14.4% | 220,989 | +2.7% | 0.00% | 0.0% |
| Q1 2017 | $5,050,000 | +31.4% | 215,155 | -31.3% | 0.00% | +33.3% |
| Q4 2016 | $3,844,000 | +28.6% | 313,267 | +80.0% | 0.00% | 0.0% |
| Q3 2016 | $2,989,000 | +147.8% | 174,036 | +105.3% | 0.00% | +200.0% |
| Q2 2016 | $1,206,000 | -17.7% | 84,788 | -20.4% | 0.00% | -50.0% |
| Q1 2016 | $1,465,000 | +440.6% | 106,540 | +561.9% | 0.00% | – |
| Q4 2015 | $271,000 | -47.5% | 16,097 | -65.8% | 0.00% | – |
| Q3 2015 | $516,000 | +4.9% | 47,064 | +19.3% | 0.00% | – |
| Q2 2015 | $492,000 | +52.8% | 39,463 | +34.7% | 0.00% | – |
| Q1 2015 | $322,000 | -56.9% | 29,299 | -39.2% | 0.00% | -100.0% |
| Q4 2014 | $747,000 | +1145.0% | 48,221 | +864.6% | 0.00% | – |
| Q3 2014 | $60,000 | +81.8% | 4,999 | +101.7% | 0.00% | – |
| Q2 2014 | $33,000 | -90.1% | 2,479 | -91.0% | 0.00% | – |
| Q1 2014 | $335,000 | -38.4% | 27,580 | -42.4% | 0.00% | – |
| Q4 2013 | $544,000 | -12.4% | 47,889 | -19.5% | 0.00% | – |
| Q3 2013 | $621,000 | +221.8% | 59,500 | +254.9% | 0.00% | – |
| Q2 2013 | $193,000 | – | 16,765 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |